Doxycycline in Type II Diabetes

Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Timeline

Start

2024-03-30

Primary completion

2026-03-20

Completion

2026-04-20

Publications

• El-Khateeb E, Khrieba MO, Badawoud AM, Morsy AA, El-Hanafy AA, Hamza E, Habba E, El-Hanafy DA, Eltantawy N, Al-Dhelaan RA, Radwan KH, El-Sayed AA, Eladaroussay MM, Rizk KAK, Ebrahim MHE, Abd Elhameed AG, Erfan IA, Elkhodary NM, Elshorbagi N, Sami HM, Dewidar SA, Mahdy MA, Zakaria H. Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes. Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun 11. doi: 10.1007/s00210-026-05510-7. Online ahead of print.

Drugs

Indications